Table 1: Study characteristics of preclinical studies.
| Clinical measure | Studies |
| No. of publications | 76 |
| No. of treatment arms | 101 |
| Source of stem cell | |
| • Rat | 30 |
| • Human | 40 |
| • Mouse | 6 |
| • Porcine | 1 |
| Species receiving stem cell | |
| • Rat | 71 |
| • Mouse | 4 |
| • Both | 1 |
| Route of administration* | |
| • IA | 34 |
| • IV | 13 |
| • IC | 33 |
| • IT | 1 |
| Range of stem cell doses | 1500-20000000 |
| Time of administration | |
| • 0-14 h | 21 |
| • 24 h | 26 |
| • > 24 h to 1 wk | 26 |
| • > 1 wk to 30 d | 5 |
| Stem cell immunogenicity | |
| • Autologous | 7 |
| • Allogeneic | 26 |
| • Xenogeneic | 44 |
| Outcome measure | |
| • Behavioural | 23 |
| • Histologic | 6 |
| • Both | 47 |
| Artery occlusion | |
| • Permanent | 24 |
| • Transient | 52 |
*Route of administration: IA: Intra-arterial; IV: Intravenous; IC: Intracerebral; IT: Intrathecal.